Now Enrolling

Pfizer mRNA Flu Vaccine

Pfizer

A Phase III, multicenter, clinical trial to evaluate the efficacy, safety, tolerability, and immunogenicity of the Pfizer quadrivalent modified RNA (modRNA) influenza vaccine candidate

Read More at Pfizer
Read More at fluvaccinestudy.com

Top of Page

AZD7442

...

A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in adults and pediatric individuals 12 years of age and older to assess the safety, immunogenicity, pharmacokinetics, and pharmacodynamics of AZD7442, a combination of two Monoclonal Antibodies (Tixagevimab and Cilgavimab), for pre-exposure prophylaxis (prevention) of COVID-19

Read More at astrazeneca.com
Read More at nejm.org
Read More at healio.com

Top of Page

RSV-MVA-004

...

A Randomized, Double-blind, Phase III trial to assess clinical efficacy, safety and reactogenicity of the recombinant MVA-BN® RSV vaccine in adults 60-years of age and older

Top of Page

#2019-01

...

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection

Read More at Micobiome.Ferring.com
Read More at Rebiotix News
Informed Consent Disclosure

Top of Page

C4591031

Pfizer

A Phase 3 Master Protocol to evaluate additional dose(s) of BNt162b2 in healthy 12 to 30 year old individuals previously vaccinated with BNt162b2

Read More
Read More
September 16 Updated Informed Consent Disclosure

Top of Page

IIT-2017-10117

...

A pilot study for Allergan's intravenous antibiotic, Dalvance® (dalbavancin), administered every 14 days for the treatment of Septic Arthritis (2 infusions) and / or Osteomyelitis (3 infusions)
Read More at Contagion Live
Read More at ClinicalTrials.gov
Read More at Contagion Live
Read More at Oxford Academic

Top of Page

Closed to Enrollment

C4591001

...

A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, Immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals.

Read more at Pfizer News
Read More at Medical Xpress
Read More at Clinical Trails Arena

Updated General Eligibility Criteria
2021 Final Informed Consent Disclosure

Top of Page

ViiV 207966

...

207966 (ATLAS 2) - A study evaluating the efficacy, safety, and tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every 4 or 8 weeks in Virologically Suppressed HIV-1-infected adults.

Read More

Top of Page